Zinman B. Wanner C. Lachin J.M. et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

N Engl J Med. 2015; 373: 2117-2128Wiviott S.D. Raz I. Bonaca M.P. et al.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

N Engl J Med. 2019; 380: 347-357Neal B. Perkovic V. Mahaffey K.W. et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 2017; 377: 644-657Perkovic V. Jardine M.J. Neal B. et al.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

N Engl J Med. 2019; 380: 2295-2306Cannon C.P. Pratley R. Dagogo-Jack S. et al.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes.

N Engl J Med. 2020; 383: 1425-1435McMurray J.J.V. Solomon S.D. Inzucchi S.E. et al.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

N Engl J Med. 2019; 381: 1995-2008Packer M. Anker S.D. Butler J. et al.

Cardiovascular and renal outcomes with empagliflozin in heart failure.

N Engl J Med. 2020; 383 (NEJMoa2022190): 1413-1424Dunlay S.M. Roger V.L. Redfield M.M.

Epidemiology of heart failure with preserved ejection fraction.

Nat Rev Cardiol. 2017; 14: 591-602McDonagh T.A. Metra M. Adamo M. et al.Authors/Task Force Members

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.

Eur J Heart Fail. 2022; 24: 4-131Fitchett D. Zinman B. Wanner C. et al.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Eur Heart J. 2016; 37: 1526-1534Kato E.T. Silverman M.G. Mosenzon O. et al.

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.

Circulation. 2019; 139: 2528-2536Berg D.D. Jhund P.S. Docherty K.F. et al.

Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction.

JAMA Cardiol. 2021; https://doi.org/10.1001/jamacardio.2020.7585Bhatt D.L. Szarek M. Steg P.G. et al.

Sotagliflozin in patients with diabetes and recent worsening heart failure.

N Engl J Med. 2020; 384: 117-128Bhatt D.L. Szarek M. Pitt B. et al.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

N Engl J Med. 2021; 384: 129-139

American College of Cardiology Virtual Annual Scientific Session (ACC 2021).

(Available at:) (Accessed February 10, 2022)Solomon S.D. McMurray J.J.V. Anand I.S. et al.

Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.

N Engl J Med. 2019; 381: 1609-1620Anker S.D. Butler J. Filippatos G.S. et al.

Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Eur J Heart Fail. 2019; 21: 1279-1287Anker S.D. Butler J. Filippatos G. et al.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

N Engl J Med. 2021; 385: 1451-1461Solomon S.D. Vaduganathan M. Claggett B.L. et al.

Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.

Circulation. 2020; 141: 352-361Lund L.H. Claggett B. Liu J. et al.

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.

Eur J Heart Fail. 2018; 20: 1230-1239Abdul-Rahim A.H. Shen L. Rush C.J. et al.

Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.

Eur J Heart Fail. 2018; 20: 1139-1145Butler J. Packer M. Filippatos G. et al.

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.

Eur Heart J. 2022; 43: 416-426McMurray J.J.V. Jackson A.M. Lam C.S.P. et al.

Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF.

Circulation. 2020; https://doi.org/10.1161/CIRCULATIONAHA.119.044491Packer M. Butler J. Zannad F. et al.

Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial.

Circulation. 2021; 144: 1284-1294Butler J. Filippatos G. Jamal Siddiqi T. et al.

Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved Trial.

Circulation. 2022; 145: 184-193Abraham W.T. Ponikowski P. Brueckmann M. et al.

Rationale and design of the EMPERIAL-preserved and EMPERIAL-reduced trials of empagliflozin in patients with chronic heart failure.

Eur J Heart Fail. 2019; 21: 932-942Abraham W.T. Lindenfeld J.A. Ponikowski P. et al.

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

Eur Heart J. 2021; 42: 700-710Nassif M.E. Windsor S.L. Borlaug B.A. et al.

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

Nat Med. 2021; 27: 1954-1960Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.

Dapagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med. 2020; 383: 1436-1446Jhund P.S. Solomon S.D. Docherty K.F. et al.

Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.

Circulation. 2021; 143: 298-309Zannad F. Ferreira J.P. Pocock S.J. et al.

Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced.

Circulation. 2021; 143: 310-321Zannad F. Ferreira J.P. Pocock S.J. et al.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Lancet. 2020; 396: 819-829Packer M. Butler J. Zannad F. et al.

Empagliflozin and major renal outcomes in heart failure.

N Engl J Med. 2021; 385: 1531-1533

Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review.

JACC Basic Transl Sci. 2020; 5: 632-644Lee M.M.Y. Petrie M.C. McMurray J.J.V. et al.

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.

Arterioscler Thromb Vasc Biol. 2020; 40: 506-522Lee M.M.Y. Brooksbank K.J.M. Wetherall K. et al.

Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).

Circulation. 2021; 143: 516-525Verma S. Mazer C.D. Yan A.T. et al.

Effect of empagliflozin on left ventricular mass in patients with Type 2 diabetes and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial.

Circulation. 2019; 140: 1693-1702Connelly K.A. Zhang Y. Visram A. et al.

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.

JACC Basic Transl Sci. 2019; 4: 27-37Ferrannini E. Muscelli E. Frascerra S. et al.

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

J Clin Invest. 2014; 124: 499-508Ferrannini E. Baldi S. Frascerra S. et al.

Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes.

Diabetes. 2016; 65: 1190-1195Solomon S.D. Boer R.A. DeMets D. et al.

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

Eur J Heart Fail. 2021; 23: 1217-1225 (Available at:) (Accessed February 10, 2022)